Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15106634 | 1.00 | BRD4 (0.41) | BRD4ALDH1A1MAPTLMNAMDM2 | |
| SCHEMBL15182047 | 1.00 | BRD4 (0.41) | BRD4ALDH1A1MAPTLMNAMDM2 | |
| SCHEMBL18591886 | 0.93 | MDM2 (0.38) | ALDH1A1MAPTLMNAMDM2HPGD | |
| SCHEMBL25695323 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAHPGDPLA2G1B | |
| SCHEMBL30410248 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAHPGDPLA2G1B | |
| SCHEMBL31498720 | 0.91 | MDM2 (0.36) | BRD4MDM2MDM4TP53BACE1 | |
| SCHEMBL23728631 | 0.90 | CASP3 (0.44) | ALDH1A1MAPTLMNAMDM2HPGD | |
| SCHEMBL15281424 | 0.90 | CASP3 (0.44) | ALDH1A1MAPTLMNAMDM2HPGD | |
| SCHEMBL872752 | 0.90 | CASP3 (0.44) | ALDH1A1MAPTLMNAMDM2HPGD | |
| SCHEMBL29424162 | 0.89 | MDM2 (0.38) | ALDH1A1MAPTMDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925881-B2 | Treatment of conditions associated with hyperinsulinaemia | TENSHA THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2569434-B1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA AND RELATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180237454-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9789120-B2 | Male contraceptive compositions and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170209461-A1 | Treatment Of Conditions Associated With Hyperinsulinaemia | TENSHA THERAPEUTICS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-8981083-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA FARBER CANCER INSTITUTE, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2571503-B1 | COMPOSITIONS AND THEIR USE IN TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| EP-2569434-A2 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | Dana-Farber Cancer Institute, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143660-A2 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | BRD4 4/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | BRD4 891/4885ALDH1A1 1723/4885MAPT 4443/4885 |
| US-20180237454-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | BRD4 4/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | BRD4 3192/4885ALDH1A1 1692/4885MAPT 4052/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | BRD4 891/4885ALDH1A1 1723/4885MAPT 4443/4885 |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | MCL1, ABL1, FLT3 | BRD4 891/4885ALDH1A1 1723/4885MAPT 4443/4885 |
| US-20170209461-A1 | Treatment Of Conditions Associated With Hyperinsulinaemia | GPR119, IAPP, SLC5A2 | BRD4 1068/4885ALDH1A1 1486/4885MAPT 3027/4885 |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | BRPF3, EP300, BRD3 | BRD4 4/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | BRPF3, EP300, BRD3 | BRD4 4/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | BRD3, BRD2, BRD4 | BRD4 3/4885ALDH1A1 4275/4885MAPT 2993/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | BRD4 4/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-10925881-B2 | Treatment of conditions associated with hyperinsulinaemia | GPR119, IAPP, SLC5A2 | BRD4 1068/4885ALDH1A1 1486/4885MAPT 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.